Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 131

Similar articles for PubMed (Select 21495215)

1.

A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial.

Schilder RJ, Blessing JA, Shahin MS, Miller DS, Tewari KS, Muller CY, Warshal DP, McMeekin S, Rotmensch J.

Int J Gynecol Cancer. 2010 Oct;20(7):1137-41.

2.

Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.

Safra T, Berman T, Yachnin A, Bruchim I, Meirovitz M, Barak F, Atlas I, Levy T, Rosengarten OS.

Int J Gynecol Cancer. 2013 Mar;23(3):475-80. doi: 10.1097/IGC.0b013e3182866944.

PMID:
23435437
3.
4.
5.

An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.

Parma G, Mancari R, Del Conte G, Scambia G, Gadducci A, Hess D, Katsaros D, Sessa C, Rinaldi A, Bertoni F, Vitali A, Catapano CV, Marsoni S, van de Velde H, Colombo N.

Int J Gynecol Cancer. 2012 Jun;22(5):792-800. doi: 10.1097/IGC.0b013e318251051a.

PMID:
22635029
6.

Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.

Pitakkarnkul S, Tangjitgamol S, Srijaipracharoen S, Manusirivithaya S, Pataradool K, Prutthiphongsit W, Khunnarong J, Thavaramara T.

Asian Pac J Cancer Prev. 2013;14(4):2421-7.

7.

A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.

Covens A, Blessing J, Bender D, Mannel R, Morgan M; Gynecologic Oncology Group.

Gynecol Oncol. 2006 Mar;100(3):586-90. Epub 2005 Oct 24.

PMID:
16249022
8.

Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.

Grisham RN, Iyer G, Sala E, Zhou Q, Iasonos A, DeLair D, Hyman DM, Aghajanian C.

Int J Gynecol Cancer. 2014 Jul;24(6):1010-4. doi: 10.1097/IGC.0000000000000190.

PMID:
24978709
9.

Increased incidence of severe gastrointestinal events with first-line paclitaxel, carboplatin, and vorinostat chemotherapy for advanced-stage epithelial ovarian, primary peritoneal, and fallopian tube cancer.

Mendivil AA, Micha JP, Brown JV 3rd, Rettenmaier MA, Abaid LN, Lopez KL, Goldstein BH.

Int J Gynecol Cancer. 2013 Mar;23(3):533-9. doi: 10.1097/IGC.0b013e31828566f1.

PMID:
23385285
10.

Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.

Bamias A, Bamia C, Zagouri F, Kostouros E, Kakoyianni K, Rodolakis A, Vlahos G, Haidopoulos D, Thomakos N, Antsaklis A, Dimopoulos MA.

Oncology. 2013;84(3):158-65. doi: 10.1159/000341366. Epub 2012 Dec 28.

PMID:
23296063
11.

Weekly paclitaxel-carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma.

Vandenput I, Vergote I, Neven P, Amant F.

Int J Gynecol Cancer. 2012 May;22(4):617-22. doi: 10.1097/IGC.0b013e31824a3385.

PMID:
22426408
12.

Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer.

Havrilesky LJ, Alvarez AA, Sayer RA, Lancaster JM, Soper JT, Berchuck A, Clarke-Pearson DL, Rodriguez GC, Carney ME.

Gynecol Oncol. 2003 Jan;88(1):51-7.

PMID:
12504627
13.

Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.

Matulonis UA, Horowitz NS, Campos SM, Lee H, Lee J, Krasner CN, Berlin S, Roche MR, Duska LR, Pereira L, Kendall D, Penson RT.

J Clin Oncol. 2008 Dec 10;26(35):5761-6. doi: 10.1200/JCO.2008.17.0282. Epub 2008 Nov 10.

14.

Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer.

Sufliarsky J, Chovanec J, Svetlovska D, Minarik T, Packan T, Kroslakova D, Lalabova R, Helpianska L, Horvathova D, Sevcik L, Spacek J, Laluha A, Tkacova V, Malec V, Rakicka G, Magdin D, Jancokova I, Dorr A, Stresko M, Habetinek V, Koza I.

Neoplasma. 2009;56(4):291-7.

PMID:
19473054
15.
16.
18.

Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602).

Goff BA, Thompson T, Greer BE, Jacobs A, Storer B; Puget Sound Oncology Consortium.

Am J Obstet Gynecol. 2003 Jun;188(6):1556-62; discussion 1562-4.

PMID:
12824993
19.

Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer.

Hagemann AR, Novetsky AP, Zighelboim I, Gao F, Massad LS, Thaker PH, Powell MA, Mutch DG, Wright JD.

Gynecol Oncol. 2013 Dec;131(3):535-40. doi: 10.1016/j.ygyno.2013.09.032. Epub 2013 Oct 4.

20.

A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study.

Coleman RL, Brady WE, McMeekin DS, Rose PG, Soper JT, Lentz SS, Hoffman JS, Shahin MS.

Gynecol Oncol. 2011 Jul;122(1):111-5. doi: 10.1016/j.ygyno.2011.03.036. Epub 2011 Apr 15.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk